Joe Biden last year pledged to improve the US government’s drug production strategy in support of the idea of curtailing corporate rights to enforce their Covid vaccine. “This is the only normal thing in the world to do,” he said during the campaign in July 2020.
But until the verdict was announced this week, many in the government and the industry doubted whether the US President would live up to his promises. Not only did a number of high-level members of his administration have been skeptical, but a few pharma officials believe the US government could also fight hard for the company’s reception.
“No one thinks Biden will take over the rehab,” [they thought] that they are very scared, “says Brandon Barford, a Washington colleague at Beacon Policy Advisers.” But before the financial crisis. [of 2008], everyone thought the fundraising would never work, so that changed. This week has shown that the medical industry is a new bank. ”
When India and South Africa first negotiated with the World Trade Organization in October last year with the idea that to stop intellectual property rights and expertise related to Covid, were quickly fired. Not only did the US and the EU oppose the cancellation of the Covid drug deal, it banned any negotiations.
Biden’s comments at the conference opened up opportunities for a change in US policy. However, even though Katherine Tai, the US ambassador to the United States, started asking questions in several departments last month, many officials think the US will continue to play the role of Donald Trump’s leadership.
“There is a compulsion to do this from the Democratic Party of Congress,” the chief pharmaceutical company chief told the Financial Times last month. “But the White House will not abandon this.”
For the next three weeks, Tai met with people who were interested in the problem, from union leaders to senior managers of vaccinators. Many attendees said it was difficult to say what Tai was planning, but people on both sides of the debate came out of the discussion believing they supported their arguments.
Asia Russell was part of a meeting with Tai on April 13 as head of Health Gap, an organization dedicated to promoting access to HIV treatment worldwide.
“I don’t think he had made up his mind when he met us,” said Russell, a controversial race leader. “But he told us that the government’s response to Covid’s crisis would not be business in the usual way, which was very encouraging.”
Two weeks later, Tai held meetings with senior executives at each of the existing companies Covid vaccine approved in or near US: Pfizer, Moderna, Johnson & Johnson, Novavax and AstraZeneca.
They he told her Facilitating the cancellation of the Travels weakens U.S. vaccine production by increasing competition for the vaccine challenges, as well as allowing Russia and China to connect with American technology. “We have made a strong case and they seem to be listening,” said a medical professional involved in the negotiations.
Those who have dealt with Tai say this anonymity is one of the biggest issues. “[Tai] he is not the person you would like to be in your game, because he will pick it up, ”said a participant in the discussion. “He has a very nice face.”
Meanwhile, senior members of the Biden organization were voicing their concerns in support of their dismissal. Gina Raimondo, trade secretary, was the most outspoken, according to a number of people who took part in the negotiations, with her department at the U.S. Patent and Trademark Office especially concerned about the temporary termination of American legal rights.
A number of people also said David Kessler, head of Operation Warp Speed, a government program that helped develop the vaccine, opposed the removal. A participant in the discussion said Kessler described it as a “third track” for the pharmaceutical industry – major calls were not affected. Kessler’s spokesman did not respond to a request for comment.
One of the most notable people to worry about the words was Anthony Fauci, a senior medical consultant and one of America’s best-known medical professionals. Two days before the election, Fauci was announced adauza Financial Times he was “skeptical” about the matter, but was concerned that it could only force the US to take longer lawsuits from pharma companies.
Fauci’s comments angered campaigners, who criticized the administration for bowing down to the reception area.
But members of the group say the anger of those who are advancing is not the key to success this day.
Instead, Tai and Jake Sullivan, a national security adviser, both said this was a lesser way to achieve the ambassador’s success for Biden officials, who were criticized for not delivering a large number of vaccines and failure to respond quickly enough to the complexities taking place at Covid in India. The lawsuits were threatening to take into account the length of WTO negotiations which would not and would not happen at all if others including the UK and the EU continued to oppose the move.
One day after Fauci made a comment, Tai presented his idea to Biden at a meeting at the Oval Office. Also in attendance were Ron Klain, senior vice president, Bruce Reed, vice president, Sullivan and Jeff Zients, chief of White House Covid’s working group. No one has ever challenged the idea; Raimondo was in Connecticut at the time, according to his department.
The president and his advisers were particularly impressed with the international community’s commitment to restoring the prize, a statement issued at the conference. “This is not a solution to the epidemic,” said a member of the council. “But it makes sense in politics.”
Human rights activists will revisit negotiations in the WTO to ensure that they are not dragged down until they stop being useful. Angela Merkel, Germany’s chancellor, has stated she will not run in the by-elections.
But Washington says whatever happens in the WTO negotiations, US pharmaceutical companies have now lost their priceless potential. This could have serious repercussions for future disputes as much as you could reduce U.S. currency, because patent protection is the basis that allows pharma companies to charge exorbitant prices without fear of competition from low-cost competitors.
“There is now a strong consensus in the Democratic Party that action needs to be taken on drug prices,” Barford said. “What the president has done to show that it can happen.”
Coronavirus business transformation
How do coronaviruses deal with problems in markets, businesses, our daily lives and the workplace? Be brief with our article on coronavirus mail.